The past week has been none too kind to the PowerShares QQQ (NASDAQ: QQQ), also known as the NASDAQ 100 tracking ETF. QQQ has tumbled 4.1%, but let's remember that the fund is up 15.4% year-to-date and the Nasdaq is the best performing of the major U.S. indexes.

Of course, much of the good fortune for QQQ and the Nasdaq Composite this year is attributable to the meteoric rise of Apple (NASDAQ: AAPL), but even shares of the iPad and iPhone maker have had a tough go of things in recent weeks, sliding 9.4% in the past month.

With that pullback, there are now a few Nasdaq constituents that have actually outperformed Apple on a year-to-date basis. Let's have a look at few Nasdaq names that are in Apple's league or even beating the tech juggernaut this year.

Lululemon Atheltica (NASDAQ: LULU):

Shares of Lululemon have surged nearly 59% year-to-date, but some of the wind has come out of the stock's sails recently as the shares have tumbled nearly 7% in the past week. Still, 59% in less than five months is impressive and it proves consumers are willing to pay up for Lululemon's pricy workout attire.

However, there are some some issues that might prove concerning. First, most of Lululemon's customers are women, but the company is looking to gain affinity among men. Most analysts that follow the company don't even realize how hard it's going to be to get most regular guys to spend up for Lululemon's apparel.

Second, Lululemon trades at almost 36 times forward earnings. Apple doesn't even have a forward P/E of 11. Any earnings misstep by Lululemon would lead to harsh selling pressure. (NASDAQ: PCLN):

Priceline was up 54% year-to-date when the market closed on Wednesday. That number is likely to be smaller by the time the market closes on Thursday following some concerning second-quarter guidance from the online travel reservations firm.

Priceline expects to earn $7.20 to $7.40 a share, excluding special charges, on an 18% to 23% revenue gain. Analysts expect a sales jump of 26.4%. The midpoint of the company's profit estimate is $7.30, less than the $7.38 forecast by analysts, according to Investor's Business Daily. That was enough to send the shares down more than 3% in after-hours trading.

Vertex Pharmaceuticals (NASDAQ: VRTX):

Vertex accounts for less than half of a percent of the Nasdaq 100's weight, but its performance has been huge recently. In the past week alone share of the biotech firm have soared more than 57% after the company announced positive trial results for its two-drug treatment for cystic fibrosis. Kalydeco along with an experimental drug, VX-809, showed improved breathing in patients participating in the trial.

This is good news not only for Vertex shareholders, but the patients as well because cystic fibrosis is currently incurable and kills most that suffer from it before they turn 40.

Related Articles
  1. Chart Advisor

    Now Could Be The Time To Buy IPOs

    There has been lots of hype around the IPO market lately. We'll take a look at whether now is the time to buy.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Economics

    Long-Term Investing Impact of the Paris Attacks

    We share some insights on how the recent terrorist attacks in Paris could impact the economy and markets going forward.
  4. Chart Advisor

    Copper Continues Its Descent

    Copper prices have been under pressure lately and based on these charts it doesn't seem that it will reverse any time soon.
  5. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  6. Mutual Funds & ETFs

    Buying Vanguard Mutual Funds Vs. ETFs

    Learn about the differences between Vanguard's mutual fund and ETF products, and discover which may be more appropriate for investors.
  7. Mutual Funds & ETFs

    ETFs Vs. Mutual Funds: Choosing For Your Retirement

    Learn about the difference between using mutual funds versus ETFs for retirement, including which investment strategies and goals are best served by each.
  8. Mutual Funds & ETFs

    How to Reinvest Dividends from ETFs

    Learn about reinvesting ETF dividends, including the benefits and drawbacks of dividend reinvestment plans (DRIPs) and manual reinvestment.
  9. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  10. Mutual Funds & ETFs

    Best 3 Vanguard Funds that Track the Top 500 Companies

    Discover the three Vanguard funds tracking the S&P 500 Index, and learn about the characteristics and historical statistics of these funds.
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>

You May Also Like

Trading Center